KNX018

KNX018 is an investigational **inhaled drug-device combination product** being developed by Kenox Pharmaceuticals as an adjunct radiosensitizer for **non-small-cell lung carcinoma**. The program has been described as a first-of-its-kind adjuvant approach intended to sensitize lung tumors to **radiation therapy**, with planned use in multimodal regimens that may also include **chemotherapy** and **PD-1-directed therapy**. Kenox has stated that the product is being developed by **repurposing marketed drugs for delivery by inhalation**, but the specific active ingredient or molecular target has not been publicly disclosed. As publicly described, KNX018 was in **preclinical development** and had completed a successful FDA pre-IND interaction in 2021.